肝癌患者血浆RASSF1A及p16基因异常甲基化检测  

Promoter hypermethylation of RASSF1A and p16 gene in plasma of patients with hepatocellular carcinoma

作　　者：何青芳[1] 严冬[2] 王立新[1] 

机构地区：[1]浙江省疾病预防控制中心慢病所,杭州310051 [2]浙江大学医学院附属第一医院

出　　处：《中国公共卫生》2010年第7期819-821,共3页Chinese Journal of Public Health

基　　金：浙江省医药卫生科学研究基金(2006A019;2007A035)

摘　　要：目的探讨血浆RASSF1A基因(Ras association domain family 1 gene)和p16基因的启动子区异常甲基化与原发性肝癌关系。方法采用甲基化特异性PCR(MSP)法,对100例原发性肝癌(HCC)患者、30例乙肝患者、30例肝硬化患者和30名健康体检者血浆中RASSF1A和p16基因的启动子区异常甲基化状况进行检测。结果 HCC患者血浆RASSF1A和p16基因异常甲基化检出率分别为38.0%(38/100)和65.0%(65/100),而乙肝患者、肝硬化患者和健康体检者均未检出,与HCC组比较,差异均有统计学意义(P=0.000);Logistic回归分析发现,患者年龄、性别、血浆甲胎蛋白(AFP)、HBsAg、p16基因(RASSF1A基因)甲基化状况等与血浆中RASSF1A基因(p16基因)异常甲基化检测结果无关(P>0.05)。结论原发性肝癌患者血浆DNA中可检测到RASSF1A基因和p16基因的甲基化;RASSF1A基因和p16基因的甲基化检测对肝癌筛查有重要意义。Objective To explore the value of promoter hypermethylation of RASSF1A gene（Ras association domain family 1 gene）and p16 gene in the plasma of hepatocellular carcinoma（HCC） patients.Methods The promoter hypermethylation status of RASSF1A and p16 gene in plasma of 100 HCC patients,30 hepatitis B patients,30 hepatocirrhosis patients and 30 health persons was detected with methylatlon specific PCR（MSP）.Results Aberrant RASSF1A and p16 methylation was found in 38.0%（38 /100） and 65.0%（65 /100） of plasma DNA among HCC patients;no methylated RASSF1A or p16 was detected in plasma samples of hepatitis B patients,hepatocirrhosis patients,or health persons（P =0.000）.Charaters of the patients including age,gender,level of alpha fetoprotein,status of HBsAg,and methylation of p16 or RASSF1A gene showed no corelation with promoter hypermethylation of RASSF1A or p16 gene（P 0.05）.Conclusion Promoter hypermethylation of RASSF1A and p16 can be detected in plasma DNA among HCC patients.This detection is valuable in the screening of HCC.

关 键 词：肝肿瘤 RASSF1A基因 P16基因 甲基化 血浆 

分 类 号：R735[医药卫生—肿瘤]